Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...

Julie Levinson Werner and Sandra Halbing of Lowenstein Sandler discuss current DEI-related practices among businesses and ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans ... but cautioned there is no guarantee a deal will be forthcoming.

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

After hours: 7:20:20 p.m. EST ...

Pre-market: 4:24:23 am GMT-5 ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

After hours: 7:59:36 pm GMT-5 ...